UK pharma major GSK today announced positive headline results from two Phase III clinical trials, ANCHOR-1 and ANCHOR-2, ...

Depemokimab has already shown its potential as a therapy for severe asthma in two other phase 3 trials – SWIFT-1 and SWIFT-2 ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise ...

Both trials met their primary endpoints, indicating a significant improvement in patients treated with the drug.

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been ...

GSK plc has announced positive results from its Phase III ANCHOR trials for depemokimab, a biologic treatment for chronic ...

GSK announces positive phase III results from ANCHOR trials for depemokimab in chronic rhinosinusitis with nasal polyps: London, UK Tuesday, October 15, 2024, 10:00 Hrs [IST] GSK ...

GSK plc (LSE/NYSE: GSK) 宣布其用于治疗慢性鼻窦炎伴鼻息肉(CRSwNP)的药物depemokimab在ANCHOR三期临床试验中取得积极成果。根据新闻稿，该试验达到了主要终点，与安慰剂加标准治疗相比，在52周内显著减少了鼻息肉大小和鼻塞程度。 Depemokimab是一种超长效生物制剂，每半年给药一次，在靶向和抑制与鼻息肉生长和阻塞相关的炎症方面显示出了前景。 GSK高级副 ...

The company has set high expectations for depemokimab, which it is also advancing in three other inflammatory diseases, including asthma.

GSK said that both the Anchor-1 and Anchor-2 trials met their co-primary endpoints of a change from baseline in total endoscopic nasal polyp score after 52 weeks, as well as a change in mean nasal ...